

10 m.p.  $79 \frac{1}{2}$  -  $84^{\circ}\text{C}$ . Moreover, <sup>a</sup> the solution of <sup>these</sup> ~~this~~ crystals in ethanol was added dropwise to water with stirring, and the precipitate formed was filtrated and dried over phosphorus pentoxide in vacuo at room temperature to give hydrocortisone 17-butyrate 21-propionate as colorless <sup>crystalline</sup> ~~crystally~~ powders, m.p.  $117 \frac{1}{2}$  -  $117.5^{\circ}\text{C}$  (decomp. at  $265 \frac{1}{2}$  -  $268^{\circ}\text{C}$ ).

P NMR: (in  $\text{C}_5\text{D}_5\text{N}$ ): 1.00(3H, s), 1.00  $\frac{1}{2}$  1.30(6H, m), 1.43(3H, s), 4.48(1H, m), 4.74(2H, d.d.,  $J=18$  Hz, 6 Hz), 5.65(1H, s).

C.M.

What we claim is:

1.  $17\alpha$ -butyryloxy- $11\beta$ -hydroxy-21-propionyloxy-4- $\alpha$ -pregnen-3,20-dione

END 2.

A method for the topical treatment of skin diseases comprising applying to the inflamed areas of the skin an anti-inflammatory amount of the compound of Claim 1.